[PDF][PDF] Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary …
A Tursi, L Allegretta, N Buccianti, ND Valle… - … of Gastrointestinal & …, 2017 - academia.edu
ABSTRACT Background & Aims: Golimumab (GOL) has been recently approved in Italy for
the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were
to assess the real-life efficacy and safety of GOL in managing UC outpatients in Italian
primary Inflammatory Bowel Diseases (IBD) centres. Methods: Consecutive UC outpatients
with at least 3-months follow-up were enrolled. Primary end-point was the induction and
maintenance of remission in UC, defined as Mayo score≤ 2, at 6-month follow-up. Results …
the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were
to assess the real-life efficacy and safety of GOL in managing UC outpatients in Italian
primary Inflammatory Bowel Diseases (IBD) centres. Methods: Consecutive UC outpatients
with at least 3-months follow-up were enrolled. Primary end-point was the induction and
maintenance of remission in UC, defined as Mayo score≤ 2, at 6-month follow-up. Results …
以上显示的是最相近的搜索结果。 查看全部搜索结果